Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Voya MI Dynamic Small Cap Fund (formerly Voya Small Company Fund) Voya Investments, LLC | “An overweight position in Amicus Therapeutics, Inc. (FOLD) contributed to performance. Amicus is a commercial stage biotechnology company focused on rare disease therapies. The stock ranked in the top 25% of the universe, driven primarily by its quality features relative to its small cap peers. During 4Q25, it delivered strong results as product sales rose both domestically and abroad. BSD Analysis: Amicus is a rare-disease biotech where execution now matters more than science. Galafold proved the company can commercialize in ultra-orphan markets with real pricing power. Investors fixate on cash burn and pipeline risk while ignoring how sticky rare-disease franchises become once established. Regulatory pathways and physician relationships create barriers that don't show up in TAM slides. The pipeline adds upside, but the base business already works. Dilution risk exists, but so does leverage to operating scale. This is biotech compounding in a narrow lane, not a binary moonshot.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
